anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a levorotatory pantoprazole sodium composition for injection, and relates to the technical field of medicine manufacturing. The main medicine of the composition comprises levorotatory pantoprazole sodium and melatonin, wherein the melatonin comprises a quick release part and a cyclodextrin-included slow release part. According to the levorotatory pantoprazole sodium composition for injection provided by the invention, the therapeutic effect of levorotatory pantoprazole sodium is improved, instability caused by oral administration of MT (Melatonin) is avoided and MT is quick to distribute and eliminate and the like, and the first pass effect of MT is reduced. The dosage of levorotatory pantoprazole sodium is reduced, and the side effect of levorotatory pantoprazole sodium is reduced. The design of dosage combining quick release and slow release is in accordance with secretion characteristic of MT, so that the problem of half-life period of MT is solved and the bioavailability of melatonin is improved. Melatonin combined with levorotatory pantoprazole sodium can be used for effectively inhibiting the secretion of gastric acid, so that the composition has a good synergistic effect for treating benign active gastric ulcer.
An examination device for a heart. An afterload device connected to the aorta provides a counterpressure by an annular space delimited between a rigid cylinder and an elastic tube inserted in the rigid cylinder. The annular space comprises a compressible medium, such as air, nitrogen gas or cabon dioxide and is connected to a reservoir providing a predetermined pressure corresponding to a diastolic pressure. The reservoir is connected to the annular space via a restriction and a back-flow valve. During diastole, the annular space is inflated by the reservoir and provides a diastolic counter pressure for providing coronary flow. During systole, the ejected fluid from the heart ventricle displaces the medium inside the annular space through the restriction to the reservoir, thereby removing energy from the fluid. The compressible medium forms a compliance. In addition, there is a preload device comprising a vertical collapsible tube forming a fluid column for preload of the atrium with a desired preload pressure without introducing air into the fluid. A pump delivers fluid to the preload device and removes fluid from the afterload device.
Tretinoin has potentially significant toxic side effects in APL patients. Patients undergoing therapy should be closely observed for signs of respiratory compromise and/or leukocytosis (see boxed WARNINGS). Supportive care appropriate for APL patients, eg, prophylaxis for bleeding, prompt therapy for infection, should be maintained during therapy with tretinoin.   


There is a risk of thrombosis (both venous and arterial) which may involve any organ system, during the first month of treatment (see ADVERSE REACTIONS). Therefore, caution should be exercised when treating patients with the combination of tretinoin and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin (see Drug Interactions). [ 3, 4]   


The ability to drive or operate machinery might be impaired in patients treated with tretinoin, particularly if they are experiencing dizziness or severe headache.   


Microdosed progesterone preparations (“minipill”) may be an inadequate method of contraception during treatment with tretinoin. [ 5]
The present invention relates to a method for exchanging data between at least two servers with use of a gateway. Preferably the method is applied to healthcare systems. Each server holds a unique federated identifier, which identifier identifies a single patient (P). Thus, it is possible for the servers to communicate with each other without having to reveal the true identity of patient. By creating one session pseudonym for each pair of providing server (12) holding relevant patient data and a requesting server (10) and by formatting an inbound session identifier related to the requesting server and an outbound session identifier related to the providing server for each session pseudonym the servers may communicate anonymous data with each other. The patient data is transferred from the at least one providing server to the requesting server and all session pseudonyms are replaced, in the requesting server, with the identifier of the requesting server for the patient (P).
Methods and apparatus for classifying subjects based on time series phenotypic data are disclosed. In one arrangement, a data receiving unit receives a set of first subject-data-units, each first subject-data-unit in the set comprising time series data representing phenotypic information about a different respective one of a plurality of subjects to be classified. A data processing unit processes the set of first subject-data-units to reduce a dimensionality of each first subject-data-unit, thereby obtaining a corresponding set of second subject-data-units having lower dimensionality than the first subject-data-units. The set of second subject-data-units is processed to cluster the second subject-data-units into a plurality of clusters. Each of one or more of the subjects is classified by determining to which cluster a second subject-data-unit corresponding to the subject belongs. The clustering comprises fitting a mean trajectory with error bounds to the time series data of each second subject-data-unit and clustering the resulting fitted mean trajectories with error bounds.
The prevent invention provides an atomizing system and device having a single authentication mechanism. The system includes at least one atomizing drug container and an atomizing device. The at least one atomized medicine container associates with an authentication code carrier and contains the atomized medicine. The atomizing device includes an atomizing module, a first power module, a control unit, an antenna module and an authentication module. The control unit controls the first power module to output the first driving voltage to directly drive the atomizing module. The antenna module is used for transmitting and receiving signals, and the authentication module is configured to perform an authentication operation associated with the authentication code carrier to determine the authenticity of the at least one atomized medicine container or the atomized medicine and to generate an authentication result signal correspondingly. The control unit determines whether to control the first power module to output the first driving voltage according to the authentication result signal.
Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a "Get to Know You" session, c) feedback, and d) follow-up treatment sessions.
1324613 Estrenes ROUSSEF UCLAF 19 April 1971 [11 Feb 1970] 36201/72 Divided out of 1324612 Heading C2U The invention comprises compounds of Formulae VI, VII, VIII, IX, X, XI and XV (wherein K is a ketal group) and their preparation by the routes shown. The conversion of IV into V or XII is effected by photolysis, e.g. with a mercury vapour lamp. In the presence of iodine V is obtained and in its absence XII is obtained. The conversion of V to VI is effected with a strong base. The conversion XII # XIII # XIV # VI is effected by the successive action of an acid, a reducing agent and an acid. The other conversions shown in the Reaction Scheme are conventional.
Penile cancer is a neglected area in terms of clinical and molecular research due to the relatively low incidence of the disease (age standardized incidence is 0.3 - 1 per 100,000 men in European countries and the USA). Inguinal nodes are impalpable in up to 80% of penile cancer patients on presentation. However, 20% of these will harbour occult metastases. Therefore radical inguinal lymphadenectomy, with its significant associated morbidity of up to 70% (and mortality), is an unnecessary surgical procedure in the majority of patients. There are presently only limited data available from small series pertaining to the role of radiological imaging modalities establishing the presence of lymph node metastases, particularly micrometastases, in patients with squamous cell carcinoma of the penis. Thus there is no clear role at the moment for radiological investigations in staging men with impalpable inguinal lymph nodes at presentation. Dynamic sentinel lymph node biopsy is an invasive procedure which utilizes lymphoscintigraphy but still requires surgical excision of the lymph nodes.

Simultaneous PET and MRI using new hybrid MRI-PET systems promises optimal spatial and temporal co-registration of structural, functional, and molecular image data. The theoretical advantages of hybrid MRI-PET scanning compared to CT-PET are better soft tissue resolution, which is advantageous for the small lymph nodes, and also decreased radiation exposure. Also, local staging of the primary penile tumour could be performed simultaneously with the inguinal lymph nodes using MRI-PET. If effective, MRI-PET would provide a single non-invasive imaging test that would replace dynamic sentinel lymph node biopsy (which is operator dependent, involves a general anaesthetic, in-patient hospital stay and has associated morbidity) in the detection of micrometastatic deposits in those patients with cN0 (impalpable inguinal lymph nodes) disease. In addition to this, a single MRI-PET sequence will also stage the primary lesion.

University College London Hospital (UCLH) manages the largest number of penile cancer patients in the United Kingdom (UK). Hybrid MRI-PET is a new imaging modality which could result in significant cost savings, and more importantly, avoid invasive operative procedures necessitating in-patient hospital stay (with the associated potential for significant morbidity). UCLH currently has the only hybrid MRI-PET scanner in the UK. This research is unique and groundbreaking and could have a dramatic impact for penile cancer patients. Additionally, as serum, blood and frozen tissue from this cohort of patients will be collected and stored , this will provide an extremely valuable resource for future translational studies.
(1) Local Reactions:

Some swelling and redness at the site of injection is not unusual. Mild burning that occurs immediately after the injection is normal; this usually subsides in 10 to 20 seconds. If the swelling and redness persist for a period of 24 hours or longer this should be a sign to proceed with caution in increasing the dosage. With the next injection the dosage should remain the same or be decreased. Large local reactions may indicate that a systemic reaction could occur with the next injection if the dosage was increased. If a patient continues to have reactions at the maintenance dose, the patient is considered to have exceeded the maximum tolerated dosage.

(2) Systemic Reactions:

Systemic reactions occur infrequently but must be looked for in all patients, especially highly sensitive patients. Anaphylactic shock and death are always possible, therefore, physicians must be prepared for the treatment of these reactions. Systemic reactions can also be characterized by one or more of the following symptoms: angioedema, tachycardia, conjunctivitis, cough, fainting, hypotension, pallor, rhinitis, urticaria and wheezing.

Systemic reaction can be treated by the immediate application of a tourniquet above the site of injection and the administration of 0.3 to 0.5ml of 1:1000 Epinephrine-Hydrochloride subcutaneously or intramuscularly in the opposite arm. The dosage may be repeated two times at 15 minute intervals. Loosen the tourniquet at least every 10 minutes.

The pediatric dosage for 1:1000 Epinephrine-Hydrochloride is 0.05 to 0.1 ml for infants to 2 years of age; 0.15ml, for children 2 to 6 years; and 0.2ml, for children 6 to 12 years.

Patients should always be observed for at least 30 minutes after any injection. Hypotension can be reversed by using vasopressor agents and volume expanders. Parenteral aminophylline and inhalation bronchodilators may be required for bronchospasm. Oxygen may also be needed. Maintenance of an open airway is critical if upper airway obstruction is present. Adrenal corticosteroids and intravenous antihistamine can be given after adequate epinephrine and circulatory support has been administered. Physicians must be familiar with these systemic reactions and have all the equipment and drugs necessary for proper treatment. (8)

Serious adverse reactions can be reported to the US Food and Drug Administration MedWatch Program. The MedWatch forms can be obtained by calling 1-800-FDA-1088. The address is: MedWatch, 5600 Fishers Lane, Rockville, MD, 20852-9787.
Patients were randomized during the percutaneous coronary intervention before stent implantation and assigned to the study arm using an electronic spreadsheet indicating the group assignment by random numbers. The patients will be 1:1 randomized to 2 groups: DynamX Bioadaptor and DESyne DES groups.
Pregnant women who meet the inclusion criteria assigned to the Pecha Kucha group will be informed about the study and their written and verbal consent will be obtained. Pregnant women will be asked to fill out the 'Introductory Characteristics Information Form', the 'Antenatal Breastfeeding Self-Efficacy Scale Short Form' and the 'Infant Feeding Attitude Scale (IOWA)' before the training at the first encounter, and then breastfeeding training prepared by the Pecha Kucha method will be given. 2 weeks after the training, she will be followed up by phone and asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M) scale. 4 weeks after the training, she will be asked to answer the Pospartum Breastfeeding Self-Efficacy Scale Short Form, Infant Feeding Attitude Scale (IOWA) and Visual Comparison Scale Satisfaction (VAS-M) scale.
Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
In recent years, osteoporosis has become a major public health problem in the United States. Osteoporosis can best be prevented by optimizing bone mineral gain and reducing bone loss. Because the rate of bone development reaches its peak during adolescence, fostering bone health in childhood is of critical importance. Although there have been many studies of exercise and nutritional factors that influence bone mass in adults, few randomized, prospective studies have been conducted in children. This study will determine whether parent training is effective in increasing children's calcium intake, strength, and frequency of aerobic exercise.

Families will be randomly assigned to either the physical activity and nutrition intervention group or to the injury prevention control group. Families in both groups will undergo training during 9 weekly classes. The intervention training will emphasize health topics, principles of behavior, and contingency management techniques. Post-training coaching procedures will be provided periodically for 9 months. Coaching procedures will assist parents with problem solving and help them refine and maintain parenting skills. All families will be assessed prior to training and at Months 3, 9, and 12. Outcome measures will include 24-hour recall estimates of change in diet and change in physical activity. Total bone calcium, bone density, body composition, and skeletal age will also be assessed.
306,881. Shimizu, T. Feb. 18, 1929. [A Specification was laid open io inspection under Sect. 91 of the Acts, Feb. 27, 1929]. Vitamins.-Vitamin A is extracted from suitable materials such as egg yolk, cod liver oil, tomato, spinach, and green algae, by removing cholesterol and the like from the uusaponifiable portion, and precipitating the vitamin as a choleic acid from which the free vitamin mav be obtained. In an example, cod liver oil is saponified with alcoholic potash and alcoholic solution of an alkaline earth salt such as calcium .chloride is added, the precipitated alkaline earth soaps being removed. The filtrate is treated with an acid such as carbonic acid to convert any free inorganic base into insoluble salts such as carbonates or bicarbonates, which are removed. The alcohol is then evaporated, and the residue dissolved in a solvent immiscible with water such as acetic ester, benzene, or ether. The solution is washed with soda, trisodium phosphate &.c. to remove acids, then with water or dilute acids such as hydrochloric or sulphuric acid, and is then evaporated to remove the solvent. The oily partly crystalline residue is dissolved in a small quantity of an organic solvent such as methyl or ethyl alcohol, acetone, or ethyl acetate and cooled to crystallize out cholesterol. The mother-liquor is evaporated and the dark brown oil which separates is dissolved in a suitable solvent such as methyl or ethyl alcohol or acetone, and desoxycholic acid or other bile acid adapted to form choleic acids (such as apocholic or bufodesoxycholic acid) is added. To cause the evaporation of a choleic acid the solution may be heated or evaporated and taken up in the same solvent, repeatedly if necessary. Water is added with stirring until the fluorescence disappears and the solution remains clear when warm. On cooling the vitamin A choleic acid crystallizes, the mother-liquor containing other vitamins such as D and E, which mav be recovered from it. The crvstals are allowed to stand in contact with ether, chloroform, or the like to purify them, and have the empirical formula (C24H40O4)5. C27H44O2.H2O. To obtain the free vitamin, the choleic acid may be boiled with a large excess of a substance which forms a choleic acid, such as xylol, glacial acetic acid, or a fatty acid. On cooling the xylol choleic acid crystallizes out. The mother-liquor is freed from xylol by evaporation and the residue is taken up in the methyl or ethyl alcohol, acetones, esters, &c. On evaporation the vitamin separates in white needles of the formula C27,H44O2. Alternatively, the choleic acid may be distilled at 250‹ C. in a high vacuum. the distillate being dissolved in a small quantitv of a solvent such as alcohol and the solution concentrated and allowed to crystallize. The crystals of the vitamin A choleic acid and of the free vitamin A are relatively stable to oxygen. but the process is effected in absence of free oxygen, for instance in a nitrogen atmosphere.
The recommended starting dose is 5 mg once a day. Depending on the patient's response, the dosage can be decreased to 2.5 mg or increased to 10 mg once a day. These adjustments should occur generally at intervals of not less than 2 weeks. The recommended dosage range is 2.5-10 mg once daily. In clinical trials, doses above 10 mg daily showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events (see ADVERSE REACTIONS). Modification of the recommended dosage is usually not required in patients with renal impairment.

Felodipine extended-release tablets should regularly be taken either without food or with a light meal (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism). Felodipine extended-release tablets should be swallowed whole and not crushed or chewed.

Geriatric Use -Patients over 65 years of age are likely to develop higher plasma concentrations of felodipine (see CLINICAL PHARMACOLOGY). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range (2.5 mg daily). Elderly patients should have their blood pressure closely monitored during any dosage adjustment.

Patients with Impaired Liver Function - Patients with impaired liver function may have elevated plasma concentrations of felodipine and may respond to lower doses of felodipine extended-release tablets; therefore, patients should have their blood pressure monitored closely during dosage adjustment of felodipine extended-release tablets (see CLINICAL PHARMACOLOGY).
The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
The present embodiment relates to a method of extraction of a plurality bio-active peptides from oil palm materials such as mesocarps. The method of extraction includes the extraction of a total protein by precipitation of the total protein using phenol and methanol containing ammonium acetate. The total protein is hydrolyzed by using pepsin or trypsin, wherein the enzyme hydrolysis generates the plurality of bio-active peptides. The plurality of bio-active peptides are fractionated and the sequence of the plurality of bio-active peptides is determined. The plurality of bio-active peptides possess anti-oxidant and anti-fungal properties. Fig. 1
Of the total number of subjects in clinical studies of Meropenem for injection (I.V.), approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure infections, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 

A pharmacokinetic study with Meropenem for injection (I.V.) in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance [ see Clinical Pharmacology ( 12.3) ].